News • Controlling KRAS

New targeted gene therapy could stop lung cancer progression

A newly targeted therapy could help millions of lung cancer patients worldwide keep their cancers from spreading, says an expert at Cleveland Clinic, on the occasion of World Lung Cancer Day.

portrait of Khaled Hassan
Dr. Khaled Hassan

Image source: Cleveland Clinic

Dr. Khaled Hassan, of the Hematology and Medical Oncology Department at Cleveland Clinic, said: “The KRAS mutation is a main gene that drives cancer, and lung cancer specifically, but previously it’s been difficult to target. With the new KRAS targeted therapy, 81 percent of cancer patients kept their cancer under control, which could extend and improve patients’ lives by about six months. One third of the patients had an objective response rate, of shrinking and/or totally eliminating cancer, even though previous chemotherapy failed to control their disease. We now have targeted therapies for eight cancer-driving genes, and patients are responding very well.”

In the clinical trial - of which Dr. Hassan was not a part - about four out of five (81 percent) patients achieved disease control, meaning the cancer disappeared, went into remission, or stayed the same. About one third of total patients (36 percent) achieved an objective response rate, meaning the cancer shrunk or disappeared completely.

The two most important points are for patients to stop smoking, which can cause cancer and other diseases, and for those who are high risk to get early, safe low-dose CT scan screenings

Khaled Hassan

Worldwide, lung cancer is the second most common type of cancer, with 2.21 million new cases in 2020, and the leading cause of cancer death, at 1.8 million deaths in 2020, according to the World Health Organization. The US Food and Drug Administration (FDA) recently approved the use of a new targeted therapy for cancer tumors with the KRAS G12C mutation. The KRAS mutation accounts for approximately 25 percent of mutations in non-small cell lung cancers, and the G12C mutation represents about 13 percent of mutations in non-small cell lung cancers. “Targeted therapies are designed to be very selective to bind to the pathways of specific gene mutations, and can get rid of most of the toxicities in the cancer cells with only minor side effects,” added Dr. Hassan, who said that Cleveland Clinic is already prescribing the treatment to patients. “For the remaining patients who did not respond to this targeted therapy, we need to figure out how to develop drugs that can target the genes’ pathway to resistance.”

However, Dr. Hassan cautioned that this KRAS targeted therapy is not a cure, as eventually the cancer cells can find a way around the treatment and develop resistance. Dr. Hassan concluded: “As we mark World Lung Cancer Day, the two most important points are for patients to stop smoking, which can cause cancer and other diseases, and for those who are high risk to get early, safe low-dose CT scan screenings. The highest risk patients are 50 years or older, and have smoked at least one pack of cigarettes a day for 20 years.”

Read more about non-small cell lung cancer (NSCLC) here!

Source: Cleveland Clinic

02.08.2021

Read all latest stories

Related articles

Photo

News • Researchers develop noninvasive approach

FUSIN: Delivering gene therapy with ultrasound

Treatment of central nervous system diseases and tumors is often hindered by the blood-brain barrier. A new method aims to overcome this obstacle using focused ultrasound intranasal delivery (FUSIN).

Photo

News • Novel disease therapies

"Soft” CRISPR may offer fix for genetic defects

A new approach makes use of natural DNA repair machinery and provides a foundation for novel gene therapy strategies with the potential to cure a large spectrum of genetic diseases.

Photo

News • Cardiology research

Covid-19 vaccine technique could also save tissue after heart attack

A method for delivering genetic material to the body that has proven useful in Covid-19 vaccination is now being tested as a way to repair damaged heart muscle after a heart attack.

Related products

CliniSys – Genetics Laboratory

LIS / Middleware / POCT

CliniSys – Genetics Laboratory

CliniSys Deutschland GmbH
MolGen – PurePrep 96

Extraction

MolGen – PurePrep 96

MolGen
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Subscribe to Newsletter